Replies to post #358338 on Amarin Corp Plc (AMRN)

[Pharmacydude]

One
Another possibility is that ECLA was making too high a demand for royalties WRT patents.
ECLA owns the study and the data. Maybe they had an agreement with Amarin on allowing Amarin to use their data from PI2 in their patent applications but ECLA wanted to increase their royalties for any data from PI3 and Amarin decided to pass.
Just a thought